Daniel Skovronsky
Daniel Skovronsky is the Chief Scientific Officer at Eli Lilly and has been instrumental in advancing diabetes and obesity treatments. He recently highlighted the potential impact of a new oral GLP-1 medication, orforglipron, which could revolutionize treatment for millions suffering from type 2 diabetes and obesity.
Not in the pool (under ¢1).
Recent news mentions
Daniel Skovronsky is the chief scientist at Eli Lilly who discussed the potential affordability of the new treatment.
Prevenção definitiva do colesterol? Cientistas mostram que pode ser possível
Brazil· 2026-05-27
Daniel Skovronsky is the Chief Scientific and Product Officer at Eli Lilly, responsible for research, development, and global marketing of medications.
Nach der Abnehmspritze kommt die Pille
Switzerland· 2026-02-03
Daniel Skovronsky, the scientific director of Lilly, stated that injections cannot be the solution for billions of people around the world.
Pílula diária de GLP-1, classe do Ozempic, apresenta dados animadores de controle do peso e diabetes
Liechtenstein· 2025-04-17
